GSK Set To Begin Trials On Japan’s Third Bird-Flu Vaccine
This article was originally published in PharmAsia News
Executive SummaryJapan's Health Ministry gave GlaxoSmithKline fast-track status for its bird-flu vaccine, clearing the way for clinical trials to begin as early as this year. If successful, the GSK pre-pandemic vaccine against the H5N1 flu virus would be the third approved for marketing in Japan, which already has stockpiled enough doses for 20 million people. GSK has approval for its vaccine in the European Union. The medical community would like to have as many choices of vaccines as possible because of uncertainties surrounding a possible pandemic of the virus. (Click here for more - a subscription may be required
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.